Scarica l'app Stockscreener
85.69
1.61%
-1.40
Dopo l'orario di chiusura:
85.69
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Cameron Turtle: The $1.6 Billion Bet That IBD's 25% Ceiling Is About to Break - finance.biggo.com
Spyre Therapeutics at Stifel forum: betting on autoimmune combinations By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history - Yahoo Finance Australia
What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis? - Yahoo Finance
Spyre Therapeutics, Inc Income Statement – MUN:3920 - TradingView
Equity in earnings of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Price to cash flow ratio of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Spyre Therapeutics, Inc. (SYRE) Investor Outlook: A Biotech Stock with a Potential 29.56% Upside - DirectorsTalk Interviews
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests - Yahoo Finance
Spyre Therapeutics, Inc Statistics – GETTEX:3920 - TradingView
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Yahoo Finance
Spyre Therapeutics at Wells Fargo conference: betting on combination biologics - Investing.com Canada
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Spyre Therapeutics at Citi summit: bets on autoimmune combinations By Investing.com - Investing.com Canada
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - The Globe and Mail
Spyre Therapeutics Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com South Africa
SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada
Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com
An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan
Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Yahoo Finance
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares - investing.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares - investing.com
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares - Investing.com
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares By Investing.com - Investing.com India
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells over 25K shares in planned trades - Stock Titan
Spyre Therapeutics (SYRE) officer sells stock from option exercise at prices up to $90 - Stock Titan
Three September conferences will include Spyre Therapeutics. Webcasts will be available. - Stock Titan
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Multimillion-dollar stock sale planned by Spyre Therapeutics (SYRE) officer—see how many shares are on the block - Stock Titan
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked - finance.yahoo.com
Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles - Sahm
Spyre reveals mid-stage miss for TL1A antibody in rheumatoid arthritis - The Pharma Letter
Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade) - Seeking Alpha
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis - TradingView
Stifel reiterates Spyre stock Buy rating after RA study results By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127 - Moomoo
Stifel reiterates Spyre stock Buy rating after RA study results - Investing.com
Deutsche Bank Adjusts Spyre Therapeutics PT to $127 From $135, Maintains Buy Rating - marketscreener.com
Why is Spyre Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 - The Manila Times
Spyre reports mixed phase 2 results for SPY072 in arthritis By Investing.com - Investing.com Nigeria
Stocks to Watch : Intuit, Spyre Therapeutics, Zoom Communications, nCino - marketscreener.com
Spyre Therapeutics stock tumbles on trial results By Investing.com - Investing.com Australia
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):